Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Context Therapeutics Inc.NASDAQ: CNTX
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $67.16K (cash outflow) fell 84.6% year over year, behind the +240.3% change in trailing-twelve-month accounts payables. Sequentially, it fell 64.3% from the prior quarter.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -84.6% toward the trailing-twelve-month pace of +240.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 1.1M USD
- Year-over-year change
- +215.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.1M | +215.9% |
| FY2024 | 2024-12-31 | (946K) | -165.4% |
| FY2023 | 2023-12-31 | 1.45M | +283.6% |
| FY2022 | 2022-12-31 | (787.89K) | +9.0% |
| FY2021 | 2021-12-31 | (866.01K) | — |
Accounts Payables vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +240.3% is the 3rd highest of 8, against a peer median of -48.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | €6.32M EUR | — | +17.8% | 21552.6% | |
| LTM Mar 2026 | $3.63M USD | +320.5% | -38.0% | 51.0% | |
IMAImageneBio Inc | LTM Mar 2026 | $3.6M USD | +389.7% | — | — |
| LTM Mar 2026 | $2.31M USD | -48.2% | -70.5% | 1.5% | |
| FY2025 | $1.62M USD | +186.9% | +62.8% | 2534.4% | |
| LTM Mar 2026 | $1.46M USD | +240.3% | — | — | |
| LTM Mar 2026 | $1.44M USD | -64.1% | — | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $1.4M USD | — | — | — |
| LTM Mar 2026 | $343K USD | -64.3% | -51.8% | 34.3% | |
| LTM Mar 2026 | $104K USD | -55.2% | — | 77.6% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $0 USD | — | — | 0.0% |
| Peer median (excluding CNTX) | — | -48.2% | -38.0% | 51.0% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M |
| Change in Working Capital | (2.22M) | (277.52K) | 1.78M | (3.48M) | 6.28M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (866.01K) | (787.89K) | 1.45M | (946K) | 1.1M |
| Other Working Capital | (1.36M) | 510.37K | 329.03K | (2.53M) | 5.19M |
| Other Non-Cash Items | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M |
| Operating Cash Flow | (8.8M) | (13.55M) | (21.05M) | (14.56M) | (26.39M) |
| Capital Expenditures | (250K) | (536.84K) | 0 | (14.76M) | (33.95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (14.75M) | (2M) |
| Investing Cash Flow | (250K) | (536.84K) | 0 | (14.76M) | (2.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.41M | (102.07K) | 0 | 109.29M | (15.27K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 58.39M | (102.07K) | 0 | 109.29M | (15.27K) |
| Effect of Forex Changes | 0 | 50.39K | 0 | 0 | 0 |
| Net Change in Cash | 49.34M | (14.14M) | (21.05M) | 79.98M | (28.43M) |
| Free Cash Flow | (9.05M) | (14.09M) | (21.05M) | (29.31M) | (26.42M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.